2. Cell Cycle/DNA Damage Anti-infection
  3. ClpP Bacterial
  4. ZY39

ZY39 is a SaClpP agonist. ZY39 promotes the enzymatic hydrolysis of SaClpP and HsClpP in vitro. ZY39 inhibits the growth of Staphylococcus aureus strains. ZY39 reduces the load of Staphylococcus aureus in organs and ascites in mouse peritonitis models and zebrafish infection models, and improves the survival rate of model animals. ZY39 can be used in studies related to Staphylococcus aureus infection, such as peritonitis.

For research use only. We do not sell to patients.

ZY39

ZY39 Chemical Structure

CAS No. : 2999673-51-5

Size Price Stock Quantity
5 mg In-stock
10 mg In-stock
25 mg In-stock
50 mg In-stock
100 mg In-stock
200 mg   Get quote  
500 mg   Get quote  

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 1 Customer Validation

ZY39 Related Antibodies

Top Publications Citing Use of Products

  • Biological Activity

  • Purity & Documentation

  • References

  • Customer Review

Description

ZY39 is a SaClpP agonist. ZY39 promotes the enzymatic hydrolysis of SaClpP and HsClpP in vitro. ZY39 inhibits the growth of Staphylococcus aureus strains. ZY39 reduces the load of Staphylococcus aureus in organs and ascites in mouse peritonitis models and zebrafish infection models, and improves the survival rate of model animals. ZY39 can be used in studies related to Staphylococcus aureus infection, such as peritonitis[1].

In Vitro

ZY39 potently activates SaClpP-mediated α-casein hydrolysis in vitro with an EC50 of 1.1 μM, and exhibits agonistic activity during the hydrolysis of fluorescein isothiocyanate-casein (FITC-casein) by S. aureus ClpP protease (SaClpP), with an EC50 of 0.33 μM[1].
ZY39 activates the hydrolysis of α-casein by HsClpP in vitro with an EC50 of 3.6 μM, but exhibits extremely low activity against gut microbial ClpP (EcClpP, LaClpP)[1].
ZY39 potently inhibits the growth of both drug-sensitive and multidrug-resistant S. aureus strains in vitro. Its activity depends on functional SaClpP, with MIC values ranging from 0.031 to 0.13 μg/mL[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

ZY39 Related Antibodies
In Vivo

ZY39 (0.5-25 mg/kg; i.p.; single dose) demonstrates superior therapeutic efficacy against S. aureus USA300 infection in zebrafish compared to (R)-ZG197 or vancomycin, respectively[1].
ZY39 (25-50 mg/kg; i.p.; single dose) achieves 89-100% survival and reduces bacterial loads by 2-4 log CFU/g tissue in mice with S. aureus USA300-induced peritonitis[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: Zebrafish (7 to 11 months old, 300 mg, regardless of gender)[1]
Dosage: 0.5 mg/kg; 5 mg/kg; 25 mg/kg
Administration: i.p.; single dose
Result: Showed therapeutic effects comparable to (R)-ZG197 (HY-152096) at 25 mg/kg in zebrafish infected with a lethal inoculum of USA300 that killed all control zebrafish within 24 hours (5 mg/kg dose).
Provided significantly improved rescue rates compared to Vancomycin (HY-B0671) at the same dose in zebrafish infected with a USA300 inoculum that killed 80% of control zebrafish within 48 h (0.5 mg/kg dose).
Animal Model: ICR (CD1) mice (female, 20-22 g)[1]
Dosage: 25 mg/kg; 50 mg/kg
Administration: i.p.; single dose
Result: Resulted in 89-100% survival rates, comparable to vancomycin at 25 mg/kg (25 mg/kg and 50 mg/kg doses).
Reduced bacterial loads by 2-4 log CFU/g tissue in heart, liver, spleen, lung, kidney, and peritoneal fluid compared to vehicle controls (25 mg/kg and 50 mg/kg doses).
Provided 100% survival in S. aureus MRSA XJ049-infected mice, compared to 56% survival with oxacillin at 50 mg/kg.
Molecular Weight

548.60

Formula

C28H35F3N4O4
CAS No.
Appearance

Solid

Color

White to off-white

SMILES

FC(F)(F)CCCNC(N1[C@]2([H])N(C(CC1)=O)[C@@](C(N(C2)CC3=CC=C(OC)C4=C3C=CC=C4)=O)([H])[C@@H](C)CC)=O
Shipping

Room temperature in continental US; may vary elsewhere.
Storage

4°C, protect from light, stored under nitrogen

*In solvent : -80°C, 6 months; -20°C, 1 month (protect from light, stored under nitrogen)

Solvent & Solubility
In Vitro: 

DMSO : 100 mg/mL (182.28 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

Preparing
Stock Solutions
Concentration Solvent Mass 1 mg 5 mg 10 mg
1 mM 1.8228 mL 9.1141 mL 18.2282 mL
5 mM 0.3646 mL 1.8228 mL 3.6456 mL
View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light, stored under nitrogen). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

  • Molarity Calculator

  • Dilution Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass
=
Concentration
×
Volume
×
Molecular Weight *

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start)

C1

×
Volume (start)

V1

=
Concentration (final)

C2

×
Volume (final)

V2

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

  • Protocol 1

    Add each solvent one by one:  10% DMSO    40% PEG300    5% Tween-80    45% Saline

    Solubility: ≥ 2.5 mg/mL (4.56 mM); Clear solution

    This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

    Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

    Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
  • Protocol 2

    Add each solvent one by one:  10% DMSO    90% (20% SBE-β-CD in Saline)

    Solubility: 2.5 mg/mL (4.56 mM); Suspended solution; Need ultrasonic

    This protocol yields a suspended solution of 2.5 mg/mL. Suspended solution can be used for oral and intraperitoneal injection.

    Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

    Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
In Vivo Dissolution Calculator
Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

g

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
%
DMSO +
% 
+
%
Tween-80 +
%
Saline
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Calculation results:
Working solution concentration: mg/mL
Method for preparing stock solution: mg drug dissolved in μL  DMSO (Stock solution concentration: mg/mL).

*In solvent : -80°C, 6 months; -20°C, 1 month (protect from light, stored under nitrogen)

The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only. If necessary, please contact MedChemExpress (MCE).
Method for preparing in vivo working solution for animal experiments: Take μL DMSO stock solution, add μL . μL , mix evenly, next add μL Tween 80, mix evenly, then add μL Saline.
 If the continuous dosing period exceeds half a month, please choose this protocol carefully.
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Purity & Documentation
References

Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light, stored under nitrogen). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Optional Solvent Concentration Solvent Mass 1 mg 5 mg 10 mg 25 mg
DMSO 1 mM 1.8228 mL 9.1141 mL 18.2282 mL 45.5705 mL
5 mM 0.3646 mL 1.8228 mL 3.6456 mL 9.1141 mL
10 mM 0.1823 mL 0.9114 mL 1.8228 mL 4.5571 mL
15 mM 0.1215 mL 0.6076 mL 1.2152 mL 3.0380 mL
20 mM 0.0911 mL 0.4557 mL 0.9114 mL 2.2785 mL
25 mM 0.0729 mL 0.3646 mL 0.7291 mL 1.8228 mL
30 mM 0.0608 mL 0.3038 mL 0.6076 mL 1.5190 mL
40 mM 0.0456 mL 0.2279 mL 0.4557 mL 1.1393 mL
50 mM 0.0365 mL 0.1823 mL 0.3646 mL 0.9114 mL
60 mM 0.0304 mL 0.1519 mL 0.3038 mL 0.7595 mL
80 mM 0.0228 mL 0.1139 mL 0.2279 mL 0.5696 mL
100 mM 0.0182 mL 0.0911 mL 0.1823 mL 0.4557 mL
  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.

ZY39 Related Classifications

Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

ZY392999673-51-5ZY 39ZY-39ClpPBacterialCaseinolytic protease PSaClpP agonistStaphylococcus aureusICR (CD1) miceZebrafishperitonitisInhibitorinhibitorinhibit

Your Recently Viewed Products:

Inquiry Online

Your information is safe with us. * Required Fields.

Product Name

  

Requested Quantity *

Applicant Name *

 

Salutation

Email Address *

 

Phone Number *

Department

 

Organization Name *

City

State

Country or Region *

      

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
ZY39
Cat. No.:
HY-186109
Quantity:
MCE Japan Authorized Agent:

Customer Review

Thank You for Your Feedback!

Request for HNMR Report

Please fill out this form to request the QC report. We will send it to your Email address shortly.

Your information is safe with us. * Required Fields.

Product Name

  

Lot #

Applicant Name *

 

Email Address *

Phone Number

 

Department *

Organization Name *

 

Country or Region *

Remarks

SAFETY DATA SHEET (SDS)

English - EN (252 KB) Français - FR (252 KB) Deutsch - DE (252 KB) Norwegian - NO (252 KB) Español - ES (252 KB) Swedish - SV (252 KB) Italian - IT (252 KB) Korean - KR (252 KB) Portuguese - PT (252 KB)

Request for HNMR Report

We have received your request and will respond to you as soon as possible.